older woman drinking tea with young daughter Share on Pinterest
New research in mice may help open up new treatment avenues for Alzheimer's disease. Maskot/Getty Images
  • Worldwide, Alzheimer's disease is one of the most common forms of dementia.
  • Using mouse models, researchers in Commonwealth of australia have identified one of the probable causes of Alzheimer'south disease. Some have dubbed the finding a "breakthrough."
  • By studying the blood-brain bulwark, the scientists have come away with a better understanding of why and how Alzheimer'southward disease occurs.
  • Their findings advise potential treatment and prevention options for the neurodegenerative condition.

The Centers for Disease Command and Prevention (CDC) judge that upwardly to five.eight million people in the United states of america alive with Alzheimer's disease.

Alzheimer's affliction is a neurodegenerative condition affecting parts of the brain associated with retentivity, thought, and linguistic communication. Its symptoms range from mild memory loss to the disability to hold conversations to environmental disorientation and mood changes.

Previous research has suggested that various factors — such every bit age, family history, nutrition, and environmental factors — combine to influence a person's risk of Alzheimer's disease.

However, scientists in Australia have recently discovered an additional factor that may be responsible for the development of this neurodegenerative condition.

Lead report author Dr. John Mamo, Ph.D. — distinguished professor and manager of the Curtin Health Innovation Research Institute at Curtin University in Perth, Australia — explained to Medical News Today the conclusion from the new research.

He said, "To find new opportunities to prevent and care for Alzheimer's, we demand to sympathize what really causes the disease, and before long that is not established."

"This study," he added, "shows that exaggerated abundance in blood of potentially toxic fat-poly peptide complexes tin can damage microscopic brain blood vessels called capillaries and, thereafter, leak into the brain, causing inflammation and brain prison cell death."

"[Changes] in dietary behaviors and certain medications could potentially reduce claret concentration of these toxic fat-poly peptide complexes, [subsequently] reducing the risk for Alzheimer'south or [slowing] downwards the disease progression," he concluded.

The findings appear in the journal PLOS Biology.

Dr. Mamo and his team are working to unearth previously undiscovered causes of Alzheimer'south disease. Their promise is that this may suggest new avenues of investigation and novel potential treatments for the condition.

In their recent study, the researchers used two mouse models. They genetically modified animals in the test grouping so that their livers would produce man amyloid-beta. This is the protein office of the toxic poly peptide-fat circuitous that the scientists thought may cause Alzheimer'south illness. The control group had no genetic modifications.

Over time, the researchers subjected both groups to a fear-motivated retentivity test for cognitive functions and noted the corresponding results.

Equally well as this exam of cognitive function, the scientists harvested various tissue samples from the mice, including samples from the liver, encephalon, lung, and duodenum. This was to report the affect of the homo amyloid-beta on the structure and function of these tissues.

When examining the tissue samples or conducting the cognitive tests, the scientists did not know if the mouse in question was from the test or control group. This information was just revealed once they were ready to start the statistical analysis of the results. This process is chosen blinding, and information technology is a inquiry practice that helps reduce the risk of unconscious bias.

The researchers institute that when the amyloid-beta proteins made in the liver of the examination mice combined with fats and traveled to the brain, they interfered with the proper operation of the brain's microscopic blood vessels, or capillaries.

This dysfunction in the claret-brain barrier led to the poly peptide-fat complexes leaking from the blood into the encephalon, resulting in inflammation. This inflammation occurred in both the test group and the control group, simply it started at a much younger age in the examination grouping.

Unlike in the command group, this inflammation was also associated with marked degeneration in the brain cells of the mice in the test group when examined nether a microscope. The scientists only rarely saw this neurodegeneration in the control mice, and it was usually at a much older age.

The squad also assessed a marker of neurodegeneration and found it to be approximately 2 times greater in the test mice than in command mice of the same age.

And then, it was unsurprising that during the test for cognitive function, the test mice performed approximately one-half as well as the control group at retentivity of learning.

These findings suggest explanations to long continuing questions nigh the role of amyloid-beta in Alzheimer'southward disease development.

Warren Harding, board chairman of Alzheimer's WA, revealed to MNT the significance of the report results. He said:

"Without significant medical advances like the quantum Prof. Mamo'due south squad has made, information technology is estimated that the number of Australians living with dementia will exceed 1 1000000 by 2058. […] These findings may have a significant global impact on the millions of people living with Alzheimer's disease."

Limitations of this study include the fact that the researchers simply conducted it in animal models. This ways that despite promising results, further studies — particularly in humans — are necessary.

Nevertheless, agreement how the amyloid-beta-fatty complex affects brain capillaries may open upwards potential medical options to either care for Alzheimer's disease or deadening down the condition's progression.

Of course, in that location is a long journey from studies in mice to treatments in people, but such laboratory research is crucial to making the advances needed to tackle this astringent, and increasingly mutual, status.

Read more about recent dementia research here.